| Clinically isolated syndrome
Betaseron vs Tascenso ODT
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Betaseron vs Tascenso Odt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTascenso Odt has a higher rate of injection site reactions vs Betaseron based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tascenso Odt but not Betaseron, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Betaseron
Tascenso Odt
At A Glance
SC injection
Every other day
Type I interferon
Oral
Daily
Sphingosine 1-phosphate receptor modulator
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Multiple Sclerosis, Relapsing-Remitting, Clinically isolated syndrome, Multiple Sclerosis, Secondary Progressive Start at 0.0625 mg (0.25 mL) SC every other day, titrating over six weeks to the recommended dose of 0.25 mg (1 mL) SC every other day.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Adults and pediatric patients (10 years and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food; pediatric patients (10 years and older) weighing 40 kg or less: 0.25 mg orally once daily, with or without food.
Contraindications
- History of hypersensitivity to natural or recombinant interferon beta, Albumin (Human), or any other component of the formulation
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the last 6 months
- History or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome without a functioning pacemaker
- Baseline QTc interval >= 500 msec
- Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
- Previous hypersensitivity reaction to fingolimod or any excipient (including rash, urticaria, or angioedema)
- Concomitant use with other products containing fingolimod
Adverse Reactions
Most common (>=5% difference from placebo) Injection site reaction, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, asthenia
Serious Hepatic injury, anaphylaxis and allergic reactions, depression and suicide, congestive heart failure, injection site necrosis, leukopenia, thrombotic microangiopathy, pulmonary arterial hypertension, seizures, drug-induced lupus erythematosus
Postmarketing Anemia, thrombocytopenia, hemolytic anemia, hypothyroidism, hyperthyroidism, pancreatitis, bronchospasm, pulmonary arterial hypertension, fatal capillary leak syndrome
Most common (>=10%) Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, pain in extremity
Serious Bradyarrhythmia, AV blocks, infections, progressive multifocal leukoencephalopathy, macular edema, liver injury, posterior reversible encephalopathy syndrome, fetal risk, malignancies, hypersensitivity reactions
Postmarketing Hemolytic anemia, thrombocytopenia, liver injury, cryptococcal infections, HPV infection, PML, arthralgia, myalgia, PRES, seizures, melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, squamous cell carcinoma, hypersensitivity
Pharmacology
Interferon beta-1b is a type I interferon that binds to specific receptors on human cell membranes, inducing immunomodulatory effects including enhancement of suppressor T cell activity, reduction of pro-inflammatory cytokine production, down-regulation of antigen presentation, and inhibition of lymphocyte trafficking into the central nervous system; its specific mechanism of action in multiple sclerosis is unknown.
Fingolimod is metabolized to fingolimod-phosphate, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts, thereby limiting lymphocyte migration into the central nervous system.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Betaseron
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Tascenso Odt
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Betaseron
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Tascenso Odt
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Betaseron
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Tascenso Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BetaseronView full Betaseron profile
Tascenso OdtView full Tascenso Odt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.